The Karma research group at Karolinska Institutet is creating the world’s best-characterised breast cancer cohort. The aim is to reduce the mortality and incidence in breast cancer through translational research focusing on breast cancer screening and prevention.

READ MORE ABOUT THE KARMA STUDY

The Karma research group at Karolinska Institutet is creating the world’s best-characterised breast cancer cohort. The aim is to reduce the mortality and incidence in breast cancer through translational research focusing on breast cancer screening and prevention.

READ MORE ABOUT THE KARMA STUDY

Recent news

2025-04-01

Full rollout of SMART

After piloting for feasibly in 2024, the SMART trial (Stockholm MAmmography Risk stratified Trial) is now in full recruitment mode. Including two main hospitals, Södersjukhuset and Capio St Göran, in the Stockholm area, covering ≈ 70% of all women included in the mammography screening program in Stockholm. SMART will recruit a total of 46 000...
2024-06-03

SMART supported by Atossa Therapeutics Inc

SMART (Stockholm MAmmography Risk stratified Trial) is a phase 2 study conducted at the mammography unit at Södersjukhuset (Stockholm South General Hospital), Sweden. The purpose of the study is to test if individualized, risk-based breast cancer screening is superior to current practice in Sweden. In SMART we will test if an individualized, imaging-based AI screening...
2023-05-17

KARISMA results: Side effects of low-dose tamoxifen

In an exploratory analysis of the KARISMA trial, we took advantage of the full 48-item KARISMA symptom questionnaire to describe the complete side effect spectra at different doses of tamoxifen in healthy women. We found that symptoms and adherence are influenced by menopausal status. Premenopausal women on 20 mg standard dose decreased in weight and...
More news
LOG IN

Log in to the Karma Research Platform here

Not a member? REGISTER HERE...
Interview

Professor Per Hall talks about Karma

See the interview (in Swedish)